Accelerating Generic Approvals by Dr Anthony Crasto

3,642 views

Published on

Accelerating Generic Approvals, keys to be the first in market, With reference to CRO'S

Published in: Health & Medicine
3 Comments
2 Likes
Statistics
Notes
No Downloads
Views
Total views
3,642
On SlideShare
0
From Embeds
0
Number of Embeds
3,067
Actions
Shares
0
Downloads
1
Comments
3
Likes
2
Embeds 0
No embeds

No notes for slide
  • Y
  • Accelerating Generic Approvals by Dr Anthony Crasto

    1. 1. Keys to being first to market with special help from CRO’S by DR ANTHONY MELVIN CRASTO Worlddrugtracker INDIA June 2016 Accelerating Generic Approvals
    2. 2. In the name of Generics, the first to market is winner At a time when most of successful drugs are reaching the patent cliff Opening the flood gates for generic substitutes Generic companies are rushing to target the best candidates and enter the market first They are relying more heavily on qualified outsource product development partners As patents expire, rush is on for first to market with generic options
    3. 3. Time largely dictates the economic profile of generic drug They are relying on Qualified contract research organisations (CRO’S) to accelerate development They get broad expertise in development processes, advanced technology, Scientific models, and infrastructre Without adding significant capital investment
    4. 4. Points for successful Bioequivalent Successful bioequivalence study Regulatory filing Process validation study Strong CRO lab partner Efficient high quality, Regulatory compliant analysis at every step Flawless execution without cost delays
    5. 5. Cont………. Bioanalytical method development Comprehensive pharma analysis Stability program support Method validation Final product testing Early phase research and development work ANDA submission Post market sample and stability testing
    6. 6. 5 Common Development Challenges
    7. 7. Preformulation and formulation Generic product must meet the same quality standards as branded products Manufacturers need toprove the efficacy of formulation by conducting, bioequivalence/bioavailability (BE/BA) Study compared with designated standard USFDA needs bioequivalence (BE) between 80-125% if the innovator product Development chemist has challenges in form of matching innovator prduct with tight acceptance criteria Also has to circumvent formulation patents
    8. 8. Contd…… Before preparing trial formulations, preformulation is done to obtain info about refernce product and drug substance Preformulation determines Active ingredients(s) Compounds Exepients Drug solubility Chemistry Flow and adsorption Drug release etc Challenge to find missing exepients from drug label of innovator
    9. 9. ++++++++ EQUIVALENCE NEEDED OR GENERIC FIRST TIME CHANGES,REDUCED DISCOVERY VERSUS GENERIC FIRST
    10. 10. Analytical resting for each likely exepient is time consuming Guesswork Lack of experience Considerable time to development process CRO can accelerate development process Advanced equipment Efficient tests Sop’s During formulation, Recipe close to innovator without impurities
    11. 11. BE/BA Studies must comply with reg requirement of country intended for marketing In USFDA has specific required in form of ANDA, Abbreviated new drug application Non patent infringing Raw material Non patent infringing formulation Stable Bioequivalent Accurate be studies will accelerate reg approvals Wrong data/less data, costly delays
    12. 12. To demonstrate bioequivalence Formulation must have same amount of active ingredient Same dissolution Release profiles Clinical BE testing Sometimes toxicological testing Onsite toxicological testing May help in Expertise Continuity Effective study oversight
    13. 13. For invitro and invivo testing Highly qualified tech and medical staff Clinical and lab investigators Sometimes human testing Need to recruit subjects, and conduct study Deep understanding of pharmacokinetic pk variability, when designing studies
    14. 14. Development of generic product must incorporate QBD, Principles Evaluate risks and minimize them Understand the formulations, pharmacokinetic and dissolution profile Understand Quality target product profile(QTPP) Modelling and simulation can aid develop drug release profile to provide bioequivalence Predict connection between dissolution and bioequivalence Develop Chemistry manufacturing and controls strategy ( CMC)
    15. 15. PLANNING TO FILE ANDA
    16. 16. An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public. A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use. All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
    17. 17. Generic drug applications are termed "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent (i.e., performs in the same manner as the innovator drug). One way scientists demonstrate bioequivalence is to measure the time it takes the generic drug to reach the bloodstream in 24 to 36 healthy, volunteers. T his gives them the rate of absorption, or bioavailability, of the generic drug, which they can then compare to that of the innovator drug. The generic version must deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the innovator drug.
    18. 18. Using bioequivalence as the basis for approving generic copies of drug products was established by the "Drug Price Competition and Patent Term Restoration Act of 1984," also known as the Waxman-Hatch Act. This Act expedites the availability of less costly generic drugs by permitting FDA to approve applications to market generic versions of brand-name drugs without conducting costly and duplicative clinical trials. At the same time, the brand-name companies can apply for up to five additional years longer patent protection for the new medicines they developed to make up for time lost while their products were going through FDA's approval process. Brand-name drugs are subject to the same bioequivalence tests as generics upon reformulation.
    19. 19. A contract research organization (CRO) is an organization that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biologic assay development, commercialization, preclinical research, clinical research, clinical trials management, and pharmacovigilance. CROs also support foundations, research institutions, and universities, in addition to governmental organizations (such as the NIH, EMA, etc.). Many CROs specifically provide clinical-study and clinical-trial support for drugs and/or medical devices. CROs range from large, international full-service organizations to small, niche specialty groups. CROs that specialize in clinical-trials services can offer their clients the expertise of moving a new drug or device from its conception to FDA/EMA marketing approval, without the drug sponsor having to maintain a staff for these services.
    20. 20. Regulatory aspects Specifically pertaining to CROs providing clinical-trials services, the International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH-GCP) (E6 1.20) defines a Contract Research Organization (CRO) as: "A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions.“ (5.2.1) A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The CRO should implement quality assurance and quality control. (5.2.2) Any trial-related duty and function that is transferred to and assumed by a CRO should be specified in writing. (5.2.3) Any trial-related duties and functions not specifically transferred to and assumed by a CRO are retained by the sponsor. (5.2.4) All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO has assumed the trial-related duties and functions of a sponsor.
    21. 21. A significant portion of R&D budgets are spent on outsourcing services (domestic and/or international) offered by the CRO industry, approximately $25 billion in 2015. As of 2015, this figure is expected to grow at 9% over the next ten to fifteen years. There are over 1,100 CROs in the world, despite continued trends toward consolidation (many CROs are being acquired in recent times or others go out of business). It is a very fragmented industry with the top 10 controlling 56.1% of the market in 2008 and down to 55% in 2009. One estimate had the size of the market set to reach $24 billion in 2010 and set to grow at a rate of 8.5% through 2015. The top CROs, according to outsourcing-pharma.com, are Quintiles, Parexel, Pharmaceutical Product Development (PPD), INC Research, Covance, Medpace, PRA Health Sciences, inVentiv Health, Meditrial Europe and Chiltern.
    22. 22. A key premise of CRO is that when it comes to health we need to have a balance between health as a right and health as a business. In the case of tropical diseases the market based incentive mechanisms do not operate. Patents as a mechanism to ensure Return on Investment (ROI) from the market fails to play the role it plays as a driver of innovation in the pharma industry. Intellectual Property as a legal system has limited role to play in fostering innovation in diseases. Therefore the CRO approach to drug discovery and development is IP neutral. Affordability and accessibility remain the core concerns of delivery of drugs for tropical diseases.
    23. 23. The only successful market based model ensuring both is the generic drug industry business model where the market competition is driving the prices to affordable levels and makes competitors seek extended market reach ensuring accessibility. The fundamental principle of CRO is affordable healthcare to the developing world. Anything that is developed in CRO will be available to the developing world in open source, generic mode, without price monopolies. This means that there will be no market monopoly associated with CRO drugs, diagnostic or delivery mechanisms.
    24. 24. Markets are the key determinants for delivery of drugs. The drugs will be discovered and developed with public funding. Once a drug is approved for use by the regulatory agencies, CRO will depend on the business model of generic drug industry which made drugs affordable in the developing countries. CRO developed drugs will be available for any industry player with appropriate manufacturing practices to distribute the drugs to the market. The market competition will ensure accessibility and affordability. CRO also understands that researchers may be contributing patented inventions to CRO or there may be cases where the inventors worked in an open source environment yet would like to file patents. CRO will encourage such patenting only for ensuring attribution to the inventors and for proving the non-obviousness of the research. In cases where CRO inventions are covered by patents, it will be used to ensure: i. Affordability and accessibility, by ensuring that the drugs are licensed non exclusively, utilizing open competition in the market, removing the monopolistic nature of IP for access in developing countries; ii. For ensuring quality control of downstream drug manufacturing, by licensing to only those entities who employs quality processes; iii. That the subsequent innovations which follows on the existing patent developed in open source also in open source through its drug clauses.
    25. 25. LIONEL MY SON He was only in first standard in school when I was hit by a deadly one in a million spine stroke called acute transverse mylitis, it made me 90% paralysed and bound to a wheel chair, He cried bitterly and we had never seen him so depressed Now I keep Lionel as my source of inspiration and helping millions, thanks to millions of my readers who keep me going and help me to keep my son and family happy.
    26. 26. MY BLOGS ORGANIC SPECTROSCOPY INTERNATIONAL LINK….. http://orgspectroscopyint.blogspot.in/ ORGANIC SPECTROSCOPY INTERNATIONAL Organic Chemists from Industry and academics to Interact on Spectroscopy Techniques for Organic Compounds ie NMR, MASS, IR, UV Etc. Starters, Learners, advanced, all alike, contains content which is basic or advanced, by Dr Anthony Melvin Crasto, Worlddrugtracker, email me ........... amcrasto@gmail.com, call +91 9323115463
    27. 27. https://newdrugapprovals.org/
    28. 28. To take full advantage of Chemical Web content, it is essential to use several Software:Winzip,Chemscape Chime, Shockwave, Adobe Acrobat, Cosmo Player, Web Lab Viewer, Paint Shop Pro, Rasmol, ChemOffice, Quick Time,etc
    29. 29. *

    ×